Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vivos Therapeutics Inc (VVOS)

Vivos Therapeutics Inc (VVOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,473
  • Shares Outstanding, K 4,835
  • Annual Sales, $ 13,800 K
  • Annual Income, $ -13,580 K
  • EBIT $ -12 M
  • EBITDA $ -11 M
  • 60-Month Beta 7.71
  • Price/Sales 1.03
  • Price/Cash Flow N/A
  • Price/Book 1.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.67
  • Number of Estimates 1
  • High Estimate -0.67
  • Low Estimate -0.67
  • Prior Year -3.05
  • Growth Rate Est. (year over year) +78.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +27.49%
on 11/19/24
3.48 -8.05%
on 11/11/24
+0.57 (+21.67%)
since 10/22/24
3-Month
2.22 +43.82%
on 10/10/24
5.95 -46.22%
on 09/18/24
+0.50 (+18.53%)
since 08/22/24
52-Week
1.91 +67.54%
on 05/30/24
48.79 -93.44%
on 11/29/23
-0.79 (-19.80%)
since 11/22/23

Most Recent Stories

More News
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

VVOS : 3.20 (+8.47%)
Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams

Vivos Therapeutics Announces Strategic Agreements with Ormco and On Demand Orthodontist Vivos Therapeutics, Inc. (NASDAQ: VVOS), a prominent medical device

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances

Vivos Therapeutics, Inc . (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearances by the Therapeutic Goods Administration for multiple indications to include the treatment...

VVOS : 3.20 (+8.47%)
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea

Study Recently Presented at the SLEEP 2022 Annual Meeting...

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call

Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET...

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method

New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues...

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Management to Host Conference Call Today at 5:00 pm ET ...

VVOS : 3.20 (+8.47%)
Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call

Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET...

VVOS : 3.20 (+8.47%)

Business Summary

Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado.

See More

Key Turning Points

3rd Resistance Point 3.60
2nd Resistance Point 3.44
1st Resistance Point 3.32
Last Price 3.20
1st Support Level 3.04
2nd Support Level 2.88
3rd Support Level 2.76

See More

52-Week High 48.79
Fibonacci 61.8% 30.88
Fibonacci 50% 25.35
Fibonacci 38.2% 19.82
Last Price 3.20
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar